>>Description of the research protocol "CF-301-102"

A Multicenter, Double-Blind, Randomized, Comparative Study of the Safety, Tolerability, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Standard-of-Care Antibacterial Therapy for the Tretament of Adult Patients with Staphylococcus aureu
Phase II study| Status : Ongoing (but closed to recruitment)

Additional details

Indication (or studied pathology) : Septicémie
Brugmann identifier : CF-301-102
EudraCT identifier : 2016-003059-31


Involved department : Infectiology
Principal investigator : Maillart
Sponsor : ContraFect Corporation
Contact : Clinical Research Unit

>This protocol was approved by the KU Leuven ethics committee.